Congress mandates free prostate screening for high-risk men, targeting health disparities

What it does

This bill requires health insurance plans to cover prostate cancer screening without cost-sharing (copays, deductibles) for men age 40+ who are at high risk—specifically African-American men and men with a family history of prostate cancer. The bill cites disparities in prostate cancer diagnosis and mortality, particularly among African-American men, and aims to remove financial barriers to early detection.

Why we flagged it

The bill's core function is to mandate insurance coverage of prostate cancer screening for a defined high-risk population without cost-sharing. It is a public health measure, not a market intervention or corporate benefit.

What the text implies

• The bill defines 'high-risk' narrowly (African-American men and family history), which may exclude other at-risk populations and could create a two-tier screening landscape where some men receive covered screening and others do not.
• The effective date (January 1, 2025) is retroactive to the bill's introduction, suggesting intent for immediate implementation if passed, which may create administrative burden for insurers mid-year.
• A clarification regarding breast cancer screening (referencing November 2009 USPSTF recommendations) appears unrelated to prostate screening and may signal an attempt to lock in older breast cancer guidance, potentially limiting coverage updates.

Who it affects

Ordinary people—particularly African-American men and those with family history—gain access to preventive screening without out-of-pocket costs, potentially enabling earlier detection when survival rates are near 100%. The public health benefit of early detection outweighs the modest insurance cost of screening.

Who stands to gain

• health insurance issuers (may face increased claims costs)
• diagnostic testing companies (PSA test providers)
• urology and oncology practices

Named in the bill

US Preventive Services Task Force (USPSTF), Public Health Service Act Section 2713, African-American men, prostate cancer, health insurance issuers, group health plans

Where it stands

6 cosponsors: 6 Democrats.

• Jan 29, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 29, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Mar 19, 2026 — Hearing held · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Hearings held”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,526,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

John Boozman, the sponsor, reported $280,200 in PAC receipts in the 2026 cycle.

• Astellas Pharma Us, Inc. — $1,490,000 on 2 filings
• Dana-farber Cancer Institute — $36,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.